OMass Therapeutics, a UK BioTech company developing small molecule therapeutics against highly validated target ecosystems, announced an oversubscribed €275 million (£230 million) Series C round.
The round was co-led by new investors Bain Capital Life Sciences, Forbion and Novo Holdings, with additional participation from Janus Henderson Investors, SV Health Investors and Jefferson Life Sciences. Each of the Company’s existing investors also participated in the round, including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank and University of Oxford.
“This financing comes at an exciting point in OMass’ evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow,” says Ros Deegan, Chief Executive Officer of OMass Therapeutics. “We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programmes in endocrinology and immunology into the clinic.
“With the backing of an outstanding group of new and existing investors, we are entering our next phase of growth with the resources to translate that progress into a portfolio of clinically differentiated medicines for patients.”
OMass’ Series C comes amid several significant European therapeutics funding rounds in 2026.
In France, Bionyra Pharma secured €143 million to advance treatments for inflammatory diseases, while Denmark’s Breye Therapeutics raised €67.5 million for its oral small-molecule pipeline, in a round also co-led by Novo Holdings.
In the UK, Cambridge-based STORM Therapeutics secured €47.5 million, Microbiotica raised €42 million, Glasgow-based Mironid received €39.9 million, and London-based Alchemab Therapeutics secured €29.3 million.
Together with the Netherlands’ Laigo Bio, which secured an additional €5.5 million, these announcements represent approximately €374.7 million in newly reported financing during 2026, rising to €649.7 million when OMass’ round is included.
“OMass leverages an experienced team and a clear vision for building a leading therapeutics company that translates complex biology into differentiated medicines for patients with significant unmet needs,” adds Evan Greif, Principal at Bain Capital Life Sciences.
“The Company is executing against that vision by advancing OMS1620 and applying its proprietary discovery approach to build a broader pipeline across endocrinology and immunology. We see meaningful potential for OMS1620 to improve the treatment for patients with CAH and look forward to partnering with Ros and the team to support the Company’s strategic and patient-first approach.”
Founded in 2016, OMass was founded as a spin-out from Professor Dame Carol Robinson’s lab at the University of Oxford to translate native mass spectrometry research into novel small molecule therapeutics against historically challenging targets.
Its proprietary OdyssION drug discovery platform combines next-generation native mass spectrometry, novel biochemistry techniques and custom chemistry to interrogate drug targets within their native ecosystems, providing cell-system fidelity with cell-free precision.
“We are pleased to join a premier investor syndicate supporting OMass as the Company advances its breakthrough programs into the clinic,” says Max Klement, Partner, Venture Investments at Novo Holdings. “Each of these candidates has the potential to address substantial unmet patient needs in their respective areas of endocrinology and immunology, and we look forward to the Company’s continuing progress.”
Proceeds from the financing will support the advancement of the Company’s lead programme, OMS1620, a potential best-in-class MC2 (melanocortin-2) receptor antagonist, through Phase 2 clinical development in congenital adrenal hyperplasia (CAH), as well as ACTH-dependent Cushing’s syndrome.
OMS1620 has been designed to increase receptor residency time and maintain activity in the presence of rising endogenous ACTH levels. This can allow more patients with CAH to achieve androgen normalisation while on physiologic doses of glucocorticoids.
The financing will also support OMass’ earlier-stage pipeline, including generation of initial clinical data for a potential first-in-class SLC15A4 inhibitor for lupus and other diseases associated with interferon overproduction and pathogenic B-cell activation.
